Kornimate/medical-research-clean huggingface dataset:
adaptation of locomotor activity in patients suffering from hip oa - analysis of this adaptation as a prognostic criterion for future disease progression

Conditions: Primary Hip Osteoarthritis

Summary: to assess the prognostic value of a characteristic evaluation of gait in persons suffering from hip oa for subsequent indications for thr.


Eligibility criteria:
inclusion criteria: * men or women aged between 45 and 75 years suffering from primary hip osteoarthritis defined according to acr criteria who presented pain in the hip for at least one month in the preceding 3 months radiological stage ii, iii or iv hip oa according to the kellgren and lawrence classification patients able to understand simple instructions des packaging instructions, to give their written informed consent. exclusion criteria: * indication for thr at the time of inclusion. pregnant or breast-feeding women alzheimer's disease chronic respiratory insufficiency with clinical manifestations parkinson's disease motor neuron disease major musculo-skeletal disorder (other than hip oa) severe non-stabilised diabetes non-stabilised hypertension hip oa inflammation flare rapidly-destructive hip oa radiography to evaluate structural evolution of the disease done more than 12 months previously presence of oa in another joint, or another osteoarticular or periarticular disease of the lower limbs with, in the opinion of the patient, disability due to this other disease that is greater than the disability caused by the hip oa. spine disease causing gait disturbance (radiculalgia, lumbar canal stenosis,... with, in the opinion of the patient, disability due to this other disease that is greater than the disability caused by the hip oa.)
research on identifying and treatment prognosis of chronic rhinosinusitis based on image and sequencing data

Conditions: Chronic Sinusitis; Radiology; Pathology; Surgery; Progression

Summary: this project focuses on researching chronic rhinosinusitis in patients, employing image processing techniques and molecular biology methods to jointly determine the research objectives: 1. investigating heterogeneity. 2. developing an intelligent assessment model. 3. creating a visual tool for diagnosis and prognosis.

1. investigating the heterogeneity of chronic rhinosinusitis: the project will utilize high-throughput information from various sources such as radiology, pathology, and proteomics to gain insights into the multi-dimensional and big data aspects of chronic rhinosinusitis. by analyzing this data, the study aims to identify and understand the different subtypes with more precise and personalized treatment approaches. 2. developing an intelligent assessment model: using artificial intelligence algorithms, the project will analyze multi-omics data gathered from the research. the goal is to establish an intelligent assessment model that can accurately interpret the data and provide valuable insights into chronic rhinosinusitis. 3. creating a visual tool for diagnosis and prognosis: the project seeks to integrate multi-omics information to establish an ai model for typing and prognostic prediction. by achieving these research objectives, this project aspires to enhance the understanding of chronic rhinosinusitis and contribute to the development of more precise, personalized, and effective treatment strategies for patients suffering from this condition.

Eligibility criteria:
inclusion criteria: 1. oral glucocorticoid, and intranasal steroid spray and steroid irrigation treatment were discontinued at least 3 months and 1 month before surgery, respectively; 2. without acute asthma episode or acute upper airway infection within 1 month before surgery; 3. not under allergen immunotherapy or biologic treatment. exclusion criteria: 1. fungal sinusitis; 2. antrochoanal polyps; 3. cystic fibrosis, vasculitis, primary ciliary dyskinesia, or immunodeficiency; 4. odontogenic maxillary sinusitis; 5. patients with history of craniocerebral trauma or sinonasal tumours. 6. insufficient ct quality (e.g., metal artifacts, motion artifacts, and lack of intact ct scan of sinuses); 7. slice thickness more than 2.5 mm. 8. women must not be pregnant, or breast-feeding; 9. patients with serious metabolic, cardiovascular, autoimmune, neurology, blood, digestive, cerebrovascular, or respiratory system disease, or any disease interfering with the evaluation of results or affecting subjects safety are excluded, such as glaucoma and tuberculosis; 10. patients with emotional or mental problems are excluded; 11. patients unsuitable for inclusion based on judgement of researchers are excluded;

Keywords: chronic sinusitis radiology progression
metabolic and metagenomic effects of intestinal microbiome repopulation in unexplained atherosclerosis

Conditions: Atherosclerosis; Intestinal Microbiome

Summary: patients with unexplained atherosclerosis (severe atherosclerosis not explained by traditional risk factors) will receive fecal microbial transplants (fmt) from patients with a protected phenotype (patients who have high levels of risk factors but little or no carotid atherosclerosis). the objective is to determine what changes in the intestinal microbiome are associated with a decline in plasma levels of toxic metabolites of the itnestinal microbiome such as trimethylamine n-oxide (tmao) and p-cresylsulfate. the intention is to develop an ecosystem therapeutic of cultured bacteria to treat atherosclerosis.

100 patients with unexplained atherosclerosis, and 5 donors with the protected phenotype will be recruited; there will be extensive microbial, viral and parasitic screening of the donors. recipients will be randomized to receive capsules of stool from the donors, or cellulose placebo. recipients will take cloxacillin 500 mg 4 times daily for 5 days before the fmt, and will undergo purging with an electrolyte solution, (peglyte) the day before the fmt. metagenomic analysis of the recipient stool will be performed before fmt, 6 weeks later and after 12 months.plasma levels of toxic intestinal metabolites will be measured before fmt, at 6 weeks and 12 months after fmt; the levels to be measured will be tmao, p-cresylsulfate, hippuric acid. indoxyl sulfate, p-cresyl glucuronide. phenyl acetyl glutamine, and phenyl sulfate. the investigators will analyze the metagenomic changes in the intestinal microbiome of recipients that are associated with decline in the plasma levels of the metabolic products of the intestinal microbiome to identify candidate bacteria for an "ecosystem therapeutic for atherosclerosis. based on previous experience of designing such a therapeutic for clostridium difficile, it is anticipated that \~ 40 bacterial species would be needed.

Eligibility criteria:
inclusion criteria: * severe atherosclerosis, with total plaque area in the top quartile (\>119 mm2), not explained by traditional risk factors in linear regression (residual score \>= 2) exclusion criteria: * excluded will be patients unwilling/unable to provide informed consent, unwilling to ingest the stool capsules at baseline, patients with moderate to severe renal failure (egfr\ 80).
anti-cytokine therapy for vasculitis

Conditions: Wegener's Granulomatosis; Renal Limited Vasculitis; Microscopic Polyangiitis

Summary: the purpose of this study is to determine whether infliximab (monoclonal anti-tumour necrosis factor alpha antibodies) are safe and effective in the treatment of anti-neutrophil cytoplasm antibody (anca) associated vasculitis.

anti-neutrophil cytoplasm antibody (anca) associated vasculitis is a life-threatening systemic inflammatory autoimmune disease. current treatment regimes using corticosteroids and cyclophosphamide have improved patient survival but are associated with treatment associated morbidity and mortality. tumour necrosis factor alpha (tnf) is a proinflammatory cytokine which has been implicated in the pathogenesis of anca vasculitis. anti-tnf therapies have been used successfully in the management of other inflammatory autoimmune diseases. this phase ii cohort study has been designed to investigate the safety and efficacy of anti-tnf monoclonal antibody (infliximab) therapy for patients with anca associated vasculitis when used in addition to standard immunosuppressive therapy.

Eligibility criteria:
inclusion criteria: * either newly diagnosed or relapsed anca associated vasculitis (wegener's granulomatosis, microscopic polyangiitis, renal limited vasculitis) exclusion criteria: * active infection * malignancy * pregnancy * diagnosis of churg-strauss syndrome or anti-glomerular basement membrane antibody disease

Keywords: infliximab vasculitis antitnf monoclonal antibody
expanded access program for tafasitamab (mor00208) in r/r dlbcl

Conditions: DLBCL

Summary: expanded access program (eap) to provide tafasitamab (mor208) to eligible patients with relapsed or refractory diffuse large b cell lymphoma. access to morphosys´ eap can be requested by contacting the respective cro clinigen (tafasitamab@clinigengroup.com).

this program is intended to provide access to patients with relapsed and/or refractory dlbcl who had at least one prior anti-cd20 containing regimen. patients with primary refractory disease and double/triple hit status are also eligible. patients considering this access program should have no other therapeutic option, and are not eligible for other clinical trials. the expanded access program (mor208n001) is currently available in the united states only.

Eligibility criteria:
major inclusion criteria : 1. age ≥ 18 years 2. patient able to provide written informed consent 3. histologically-confirmed diagnosis of dlbcl, including transformation from an earlier diagnosis of indolent lymphoma. 4. patients must have relapsed and/or refractory dlbcl, including primary refractory disease and double/triple hit status, after at least 1 prior anti-cd20 containing regimen. 5. patients with a serious, life-threatening illness in which conventional therapies have failed, are unsuitable and/or are unavailable and participation in ongoing relevant clinical trials is not feasible. major exclusion criteria: 1. patients who have other histological type of lymphoma, e.g. indolent non-hodgkin lymphoma (nhl), primary mediastinal b-cell lymphoma (pmbl) or burkitt lymphoma 2. patients who are not willing/able to take venous thromboembolic event prophylaxis during the entire treatment period with lenalidomide 3. patients with: 1. known active bacterial and viral and fungal infections 2. serology of chronic active viral hepatitis b and/or c-hepatitis 3. known seropositivity for or history of active viral infection with human immunodeficiency virus (hiv) 4. patients who are unable to participate in the lenalidomide rems program

Keywords: tafasitamab mor00208 mor208 monoclonal anti-cd19 antibody diffuse large b-cell lymphoma
can frailty inform the management of hypertension in older people?

Conditions: Hypertension; Frailty

Summary: the purpose of this study was to investigate in large scale routine primary care data whether frailty is a prognostic factor for relevant outcomes in the management of hypertension in older people and whether frailty causes effect modification of the association of blood pressure or blood pressure lowering treatment and outcomes in older people.

a retrospective cohort study used linked electronic health records from the welsh secure anonymised information linkage (sail) databank. all patients had hypertension in the absence of established cardiovascular disease, and were over the age of 65 years in 2007. systolic blood pressure and frailty, measured using the electronic frailty index were recorded. patients were followed up for ten years. time to event analysis measured first ever major adverse cardiovascular or cerebrovascular event (macce), all-cause mortality and injurious falls. adjustment was made for established cardiovascular risk factors.

Eligibility criteria:
inclusion criteria: * patient registered with a general practitioner contributing to sail database for at least 1 year * patient with blood pressure measured and recorded at any time after 1st january 2007 and before 1st january 2008, was used as the individual's index start date. * patient aged 65 years or older at the time of study entry. exclusion criteria: * patient did not have a diagnosis of hypertension or did not have blood pressure meeting criteria for hypertension; * patient had an established history of cardiovascular disease (previous stroke, heart failure or myocardial infarction) prior to the start date.
upper gastrointestinal perforations: a nationwide registry-based study

Conditions: Acute Abdomen

Summary: the primary aim of this project is to increase the knowledge about how perforations in the esophagus, stomach and small intestine are treated on a national level. furthermore, secondary aims include assessment of how different treatment options and type of treating facilities relate to patient survival. this will be done by studying information about all adult patients with an upper gi perforation treated in sweden during 2005-2023.


Eligibility criteria:
inclusion criteria: * age of at least 18 years * perforation in either oesophagus, stomach or small intestine * treatment carried out in sweden * diagnosis set between january 2005 and august 2023 exclusion criteria: * children

Keywords: clinical outcomes general surgery upper gastrointestinal perforation
monitoring mitophagy in myeloid cells upon intensive care

Conditions: Septicemia

Summary: severe infections (sepsis) are a frequent cause of admission to the intensive care unit. sepsis represent a significant risk for the health of patients in the short and medium term. sepsis are notably linked to a change in the function of immune cells. in some patients, a state of pseudo-dormancy of monocyte and macrophage immune cells, called myeloid cell immunosuppression, is observed. this situation, which leads to a worsening of the infection, must be avoided because it represents a danger for the patient, even during antibiotic therapy. at present, these events are still very poorly understood. research is needed to understand how the immunosuppression of myeloid cells occurs in order to adapt existing treatments or to find new ones. laboratory work on animal models of sepsis has shown that this state of myeloid cell immunosuppression is closely linked to a modification of energy production by myeloid cells (monocytes and macrophages). the function of the mitochondria ("energy factory" of the cells) in these cells is impaired. thus, restoring mitochondrial function in myeloid cells could be a therapeutic solution against the immunosuppression of myeloid cells during severe sepsis. the aim of this study is to verify whether alterations in mitochondrial function in myeloid cells occur in both patients with and without bacterial infection.


Eligibility criteria:
inclusion criteria: criteria common to all 4 groups: * patient (and/or trusted person/health care proxy or relative) or volunteer who provided oral consent after receiving information about the study, or patient included in emergency situation * age ≥ 18 years common criteria for patients - admission to the intensive care unit or the anesthesia and intensive care unit of the dijon university hospital exclusion criteria: * person not affiliated to national health insurance * person subject to a measure of legal protection (curatorship, guardianship) * person subject to limited judicial protection * pregnancy or breastfeeding * known primary or secondary immune deficiency (radiotherapy, chemotherapy, immunosuppressive treatment or systemic corticosteroid therapy in the 3 months preceding inclusion (\> 0.15 mg/kg/d of prednisone equivalent for more than 2 weeks or "bolus" greater than 2mg/kg/d of prednisone equivalent), hiv infection, primary cellular immune deficiency) * patients hospitalized within 3 months prior to inclusion for sepsis. * patients receiving therapy known to modulate mitochondrial function, mitochondrial biogenesis or mitophagy (chloroquine, hydroxychloroquine, rapamycin, carbamazepine, resveratrol, sildenafil) * patients with covid-19
renal cysts and primary aldosteronism

Conditions: Primary Aldosteronism

Summary: during routine subtyping of confirmed primary aldosteronism by adrenal vein sampling extra plasma samples are drawn from both renal veins and from inferior vena cava. plasma renin concentration and renin activity are analysed from these samples. adrenal computed tomographies are analysed for cysts and other possible pathology by a blinded radiologist. aim is to evaluate correlation between renal pathology and renin measurements.

aim of the study is to evaluate the prevalence of renal cysts and their association with renin concentrationand acitivity in samples from renal veins and inferior vena cava (ivc) in patients who undergo an adrenal vein sampling (avs) because of primary aldosteronism. in a prospective study up to 200 patients who have been referred to tampere university hospital for avs are recruited during 24 months. informed consent is taken. clinical, medication, radiological and laboratory information according to endcrine society guidelines is collected. interventional radiologist will draw venous blood from both renal veins and from ivc for later renin analyses. one, blinded radiologist will record renal pathology of cysts but also other abnormal radiologic features. an interim analysis will be done when 60-100 patients have been recruited or at 6-12 months from the start of the study. study will be stopped if significant difference can be found in renin measurement in patients with renal cysts compared with patients without renal cysts.

Eligibility criteria:
inclusion criteria: * confirmed primary aldosteronism according to endocrine society guidelines * adrenal vein sampling performed in tampere university hospital * informed consent exclusion criteria: -

Keywords: adrenal vein sampling renal cysts renin concentration renin activity
a study of taci（transmembrane activator and calcium-modulator and cyclophilin ligand (caml) interactor）-antibody fusion protein injection (rc18) in subjects with systemic myasthenia gravis

Conditions: Systemic Myasthenia Gravis

Summary: the purpose of this study is to initially observe the safety and effectivity of rc18 in participants with systemic myasthenia gravis.


Eligibility criteria:
inclusion criteria: 1. voluntarily signed informed consent ; 2. patient diagnosed with systemic myasthenia gravis according to the following conditions. 3. seropositive at screening for achr（acetylcholine receptor）-ab or musk（muscle specific tyrosine kinase）-ab; 4. mgfa（myasthenia gravis foundation of america） clinical classification ⅱ-iiib; 5. qmg score≥8,and qmg score\>2 in four or more items; 6. maintained any one of the stable standard treatment programs in the trial protocol. exclusion criteria: 1. combined autoimmune diseases, such as systemic lupus erythematosus,rheumatoid arthritis, systemic sclerosis and so on,except for hypothyroidism and hyperthyroidism; 2. abnormal laboratory parameters need to be excluded, including but not limited to: 3. immunosuppressive agents except agents of standard treatment programs were used within one month prior to randomization.; 4. use of biological agents for targeted therapy within 6 months prior to randomization; 5. intravenous immunoglobulin therapy or plasma exchange therapy within 2 months before randomization; 6. active infection during screening(for example,herpes zoster,hiv antibody positive,active tuberculosis,etc); 7. currently suffering from active hepatitis or severe liver lesions and history; 8. diabetics with poor blood sugar control:hbalc\>9.0% or fbg≥11.1mmol/l; 9. currently having a thymic tumor ,or had a thymectomy within 6 months prior to screening; 10. received live vaccines within 3 months before randomization,or scheduled to administer vaccine during the trial; 11. malignant tumor patients; 12. allergic to human biological preparations; 13. have participated in any clinical trial within 28 days before randomization,or in 5 times half-life period of the drugs of any clinical trial(taking the longer time). 14. pregnant , lactating women and men or women who have birth plans during the research; 15. having alcohol or drug abuse that affect the experimental conditions; 16. investigator considers candidates not appropriating for the study.
efficacy and safety of remo-wax for removal of impacted earwax

Conditions: Cerumen Impaction of Both Ears

Summary: the study evaluates if remo-wax ear drops can soften impacted earwax.

this is an open, single-arm multicentre study to confirm the efficacy and safety of a commercially available remo-wax ear drops containing allantoin for dissolving and removing impacted earwax. subjects that qualify for enrollment and provide informed consent wil be treated with topical earwax softening product.

Eligibility criteria:
inclusion criteria: 1. written informed consent obtained. 2. male or female patients over 1 year old who have cerumen impaction. 3. presence of excessive or impacted cerumen \[excessive or impacted cerumen is identified as causing partial (\> 50%) or complete occlusion of at least one ear canal when attempting to visualize the tympanic membrane. exclusion criteria: 1. hypersensitivity to any product ingredient(s) or history of anaphylactic/anaphylactoid reactions. 2. history of tympanic membrane perforation, tympanostomy tubes, or otitis externa in the previous 6 months. 3. external ear infection. 4. middle ear infection 5. past ear surgery. 6. otorrhea. 7. temporal bone neoplasm. 8. presence of known or suspected mastoiditis. 9. presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data (e.g. ear eczema or seborrhoea, ear canal stenosis, exostoses). 10. deafness in the contralateral ear (single sided deafness). 11. use of any ototopical drug or cerumen-removal product (with the exception of water or physiologic saline) during the preceding 3 days. 12. use of hearing aids. 13. participation in another drug study within 60 days prior to the start of the present study. 14. predictable poor compliance or inability to communicate well with the investigator.
safety and efficacy of a monoclonal antibody for treatment of rheumatoid arthritis.

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study is to determine whether a humanized monoclonal antibody (efalizumab) is safe and effective in the treatment of rheumatoid arthritis.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of moderate to severe rheumatoid arthritis. * on stable dose of methotrexate. * 18 to 80 years of age. * less than 275 lbs. exclusion criteria: * joint replacement surgery within 60 days of the start of drug dosing. * intra-articular cortisone injections within 28 days of the start of drug dosing. * pregnancy. * history of severe allergic or anaphylactic reactions. * active bacterial, viral, fungal, mycobacterium tuberculosis. * positive ppd test. * history of any opportunistic infection. * serious persisting local or systemic infection. * history of malignancy within the past five years. * received any vaccine within 28 days of the start of study drug dosing. * joint replacement therapy planned within nine months of the start of study drug dosing. * chronic disorders apart from ra affecting the joints. * significant systemic involvement secondary to ra. * copd, asthma, or other pulmonary disease. * received any dmard other than methotrexate in the 28 days prior to the start of study drug dosing. * approved biologic ra therapy during the 28 days or 7 half-lives of the drug prior to the start of drug dosing. * investigational drug and/or treatment during the 28 days or seven half-lives of the investigational drug prior to the start of study drug dosing. * liver disease or abnormal hepatic function. * serum creatinine level \> 1.5 mg/dl. * platelet count \< 125,000 cells/mm3. * wbc count \< 3,500 cells/mm3. * seropositive for hepatitis b surface antigen. * seropositive for hepatitis c antibody. * known seropositivity for hiv.